PALVELLA THERAPEUTICS, INC.
PVLANext catalyst
FDA PDUFA Date (priority review)
Get an email about PVLA's next catalysts
Track PALVELLA THERAPEUTICS (PVLA) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 1 more upcoming event in our data (Phase 2 readout).See the timeline
2 upcoming, 1 past
FDA PDUFA Date (priority review)
NDA filing. Extracted from: Palvella Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
SourcePTX-022 Phase 2 Est. Readout (LOTU)
Primary completion for PTX-022 trial (NCT07552077) in Angiokeratomas
SourceHow PVLA's past catalysts played out
Market Overview
Stock performance and key metrics
QTORIN Rapamycin Anhydrous
Microcystic Lymphatic Malformation
PTX-022
Pachyonychia Congenita
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
QTORIN Rapamycin Anhydrous | Phase 3 | Microcystic Lymphatic Malformation | - | - |
PTX-022 | Phase 3 | Pachyonychia Congenita | - | - |
Frequently asked questions
What is in PALVELLA THERAPEUTICS, INC.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in PALVELLA THERAPEUTICS, INC.'s (PVLA) pipeline across Phase 3. Its lead program is PTX-022 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is PALVELLA THERAPEUTICS, INC.'s next FDA catalyst?→
PALVELLA THERAPEUTICS, INC.'s (PVLA) next tracked catalyst is a PDUFA date expected Feb 28, 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track PVLA biotech catalysts?→
Add PVLA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow PALVELLA THERAPEUTICS, INC.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.